Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies
Abstract
Clinical trials and real-world evidence have established the benefit of chimeric antigen receptor (CAR) T-cell therapy to reduce progression of hematologic malignancies and, in some settings, increase overall survival. However, recent studies have highlighted that patients in long-term remission remain at risk of morbidity and nonrelapse mortality, primarily because of infections and subsequent myeloid malignancies. In addition, these patients may also be survivors of chemotherapy, radiation, and/or stem-cell transplant, with broad survivorship needs. Here, we provide a roadmap for the care of patients in long-term remission after CAR-T-cell therapies and discuss avenues for future research.
Fields of Study & Subjects
CAR-T cell therapy research
Lymphoma Diagnosis and Treatment
Acute Lymphoblastic Leukemia research
Publication details
- Journal / source
- Journal of Clinical Oncology
- Publisher
- American Society of Clinical Oncology (ASCO)
- Volume
- 44
- Issue
- 8
- Pages
- 698–708
- Publication date
- 11 February 2026
- Language
- EN